+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatological Therapeutics Market - Global Forecast to 2030- Product Image
Dermatological Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Dermatological Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715954
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dermatological Therapeutics Market grew from USD 62.68 billion in 2024 to USD 69.56 billion in 2025. It is expected to continue growing at a CAGR of 10.46%, reaching USD 113.92 billion by 2030.

The dermatological therapeutics sector is experiencing a pivotal era defined by cutting-edge science, shifting patient expectations, and evolving regulatory frameworks. Innovations in targeted biologic therapies and small-molecule inhibitors are reshaping treatment paradigms, while digital tools and teledermatology platforms are enhancing patient access and care continuity. Simultaneously, escalating production costs, supply-chain complexities, and new trade policies present fresh challenges for manufacturers and providers. Despite these headwinds, increasing prevalence of chronic skin disorders, rising consumer awareness, and a growing focus on personalized regimens underscore robust demand across acute and maintenance therapies. This introduction establishes the broad forces driving change and sets the stage for a deeper exploration of transformative shifts, tariff impacts, segmentation nuances, regional dynamics, and corporate strategies that define the current dermatological landscape. As we move forward, you will gain insights into how these converging factors create both opportunities and imperatives for stakeholders to adapt, innovate, and sustain growth.

Transformative Shifts in the Dermatological Therapeutics Landscape

Rapid scientific breakthroughs and evolving patient-centric models are catalyzing transformative shifts in dermatological therapeutics. First, the maturation of monoclonal antibody platforms-ranging from anti-TNF agents to IL-17 and IL-23 inhibitors-has elevated treatment efficacy for moderate to severe conditions. Concurrently, small-molecule JAK and PDE4 inhibitors are broadening options for inflammation control with oral convenience. Phototherapy protocols have advanced through refined PUVA and narrow-band UVB regimens, reducing side-effects and enhancing outpatient delivery. Topical treatments now leverage novel corticosteroid potency stratifications alongside nonsteroidal calcineurin inhibitors and vitamin D analogs to target specific skin layers. Beyond pharmacology, teledermatology and AI-powered diagnostic tools are reshaping patient engagement and adherence, enabling remote triage and continuous monitoring. Healthcare providers are integrating these digital capabilities into holistic care pathways that emphasize early intervention and long-term management. Finally, value-based contracting and collaborative R&D alliances are redefining commercial models, encouraging payers and manufacturers to align incentives around real-world outcomes. Together, these innovations and partnerships are forging a new therapeutic ecosystem focused on precision, accessibility, and sustainable value.

Cumulative Impact of United States Tariffs 2025

The introduction of cumulative United States tariffs in 2025 on select active pharmaceutical ingredients, excipients, and specialized medical devices is poised to reverberate across the dermatology supply chain. Manufacturers reliant on imported raw materials may face margin compression as tariff rates are applied to critical components for monoclonal antibodies, small molecules, and specialty creams. Distributors and contract manufacturers will likely pass through incremental costs, leading to price adjustments at hospitals, retail pharmacies, and e-commerce platforms. In response, companies are exploring strategic on-shoring of key processes and diversifying supplier portfolios to mitigate exposure. At the same time, transitional relief measures and tariff exclusions for high-impact therapies could alleviate pressures for certain biologic and phototherapy products, but these provisions require vigilant regulatory tracking. Payers may implement tighter formularies or seek deeper rebates to offset increased unit costs, potentially impacting patient access and adherence. Ultimately, the combined effect of 2025 tariff revisions and evolving reimbursement policies will demand agile operational planning, proactive stakeholder engagement, and robust cost-containment strategies.

Key Segmentation Insights

Segmentation analysis reveals that therapeutics are classified first by therapeutic class with biologic agents segmented into monoclonal antibodies-further divided into anti-TNF, IL-17 and IL-23 inhibitors-and small molecules encompassing JAK and PDE4 inhibitors, while phototherapies break down into PUVA and UVB protocols, and topical treatments range from corticosteroids across high, medium and low potency to nonsteroidal options including calcineurin inhibitors and vitamin D analogs. Disease indications drive further granularity, identifying populations with comedonal or inflammatory acne, atopic or contact dermatitis, and guttate or plaque psoriasis. Distribution channels delineate pathways through hospital and retail pharmacies as well as online platforms spanning direct-to-consumer and broader e-commerce networks, ensuring multi-touchpoint reach. Administration methods capture injectable, oral forms in capsules and tablets, and topical applications in creams, lotions and ointments tailored to site-specific delivery. Consumer demographics stratify demand by adult, pediatric and geriatric cohorts, gender segments of female and male, and income tiers spanning low, middle and high earners. Finally, end-user environments cover home-care settings, hospitals and specialty clinics, each with distinct utilization patterns and reimbursement dynamics that inform market prioritization and go-to-market tactics.

Key Regional Insights

Regional dynamics underscore unique drivers and challenges across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust R&D investment and established reimbursement frameworks support rapid adoption of high-cost biologics and novel small molecules, though pricing scrutiny and patent expirations demand portfolio differentiation. The Europe, Middle East & Africa region exhibits heterogeneous market maturity, where Western Europe’s centralized health technology assessments contrast with emerging markets that prioritize cost-effective generics and biosimilars; meanwhile, EMEA success depends on navigating varied regulatory pathways and leveraging local manufacturing collaborations. Asia-Pacific growth is propelled by increasing healthcare expenditure, expanding private insurance coverage and rising prevalence of lifestyle-linked skin conditions; market entrants must balance competitive pricing with premium offerings while adapting to diverse regulatory standards across nations. Cross-regional partnerships and digital health initiatives are increasingly vital for stakeholders aiming to scale efficiently and address unmet patient needs.

Key Company Insights

Leading companies are strategically advancing pipelines, expanding geographic reach and forging partnerships to capture dermatological market share. Aclaris Therapeutics is progressing novel topical gene-silencing agents, while Allergan’s biologics portfolio benefits from integration under AbbVie’s R&D capabilities. Almirall emphasizes European market penetration with targeted small-molecule licenses, and Amgen continues to leverage its expertise in monoclonal antibodies for psoriasis care. AstraZeneca is exploring combination regimens in early-stage dermatitis, whereas Bausch Health drives value through specialty clinic alliances. Bristol-Myers Squibb is repurposing oncology-grade inhibitors for inflammatory dermatoses, while Eli Lilly advances next-generation IL-23 antagonists. Galderma focuses on consumer skincare crossover products, and GlaxoSmithKline applies real-world evidence to support phototherapy devices. Johnson & Johnson invests in home-use digital monitoring, Leo Pharma pursues comps in high-potency topical steroids, and Merck expands its JAK inhibitor indications. Novartis deploys precision medicine frameworks, Pfizer targets pediatric eczema populations, and Sun Pharma scales cost-effective generics. Collectively, these players are aligning R&D portfolios with market access initiatives to capitalize on evolving treatment paradigms.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a multi-pronged approach to thrive. They should first accelerate localization of critical manufacturing to buffer against tariff volatility and ensure supply continuity. Simultaneously, expanding digital health offerings-such as teledermatology platforms and remote monitoring tools-will enhance patient engagement and adherence. Third, forging early partnerships with payers to co-develop value-based agreements will align incentives around clinical outcomes and cost efficiencies. Fourth, segmenting product portfolios to address high-value indications like moderate-to-severe psoriasis, while maintaining competitive generics in acne and eczema, will optimize revenue streams. Moreover, investing in real-world evidence generation and patient-reported outcomes will strengthen positioning with health technology assessment bodies. Finally, diversifying distribution via retail, hospital and e-commerce channels will broaden market penetration and mitigate channel-specific risks.

Conclusion

As the dermatological therapeutics landscape becomes increasingly sophisticated, stakeholders must integrate scientific innovation with adaptive commercial strategies. By aligning R&D investments with patient-centric outcomes, streamlining supply chains in anticipation of tariff adjustments, and leveraging digital tools to extend care beyond clinic walls, companies can secure competitive advantage. Regional customization of market access approaches and dynamic collaboration with payers will further support sustainable growth. Ultimately, the organizations that successfully meld precision medicine with operational resilience and data-driven insights will shape the future of dermatology care and deliver measurable value to providers, payers and patients alike.

Market Segmentation & Coverage

This research report categorizes the Dermatological Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologic Agents
    • Monoclonal Antibodies
      • Anti-TNF Agents
      • IL-17 Inhibitors
      • IL-23 Inhibitors
    • Small Molecules
      • JAK Inhibitors
      • PDE4 Inhibitors
  • Phototherapies
    • PUVA Therapy
    • UVB Therapy
  • Topical Treatments
    • Corticosteroids
      • High Potency
      • Low Potency
      • Medium Potency
    • Nonsteroidal Treatments
      • Calcineurin Inhibitors
      • Vitamin D Analogs
  • Acne
    • Comedonal Acne
    • Inflammatory Acne
  • Eczema
    • Atopic Dermatitis
    • Contact Dermatitis
  • Psoriasis
    • Guttate Psoriasis
    • Plaque Psoriasis
  • Hospital Pharmacies
  • Online Pharmacies
    • Direct-To-Consumer Channels
    • E-commerce Platforms
  • Retail Pharmacies
  • Injectable
  • Oral Administration
    • Capsules
    • Tablets
  • Topical Administration
    • Creams
    • Lotions
    • Ointments
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Income Level
    • High Income
    • Low Income
    • Middle Income
  • Home Care Settings
  • Hospitals
  • Specialty Clinics

This research report categorizes the Dermatological Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dermatological Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Aclaris Therapeutics Inc.
  • Allergan PLC by AbbVie Inc.
  • Almirall, LLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Galderma Laboratories, L.P.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Leo Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatological Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Biologic Agents
8.2.1. Monoclonal Antibodies
8.2.1.1. Anti-TNF Agents
8.2.1.2. IL-17 Inhibitors
8.2.1.3. IL-23 Inhibitors
8.2.2. Small Molecules
8.2.2.1. JAK Inhibitors
8.2.2.2. PDE4 Inhibitors
8.3. Phototherapies
8.3.1. PUVA Therapy
8.3.2. UVB Therapy
8.4. Topical Treatments
8.4.1. Corticosteroids
8.4.1.1. High Potency
8.4.1.2. Low Potency
8.4.1.3. Medium Potency
8.4.2. Nonsteroidal Treatments
8.4.2.1. Calcineurin Inhibitors
8.4.2.2. Vitamin D Analogs
9. Dermatological Therapeutics Market, by Disease Indication
9.1. Introduction
9.2. Acne
9.2.1. Comedonal Acne
9.2.2. Inflammatory Acne
9.3. Eczema
9.3.1. Atopic Dermatitis
9.3.2. Contact Dermatitis
9.4. Psoriasis
9.4.1. Guttate Psoriasis
9.4.2. Plaque Psoriasis
10. Dermatological Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.3.1. Direct-To-Consumer Channels
10.3.2. E-commerce Platforms
10.4. Retail Pharmacies
11. Dermatological Therapeutics Market, by Application Method
11.1. Introduction
11.2. Injectable
11.3. Oral Administration
11.3.1. Capsules
11.3.2. Tablets
11.4. Topical Administration
11.4.1. Creams
11.4.2. Lotions
11.4.3. Ointments
12. Dermatological Therapeutics Market, by Consumer Demographics
12.1. Introduction
12.2. Age Group
12.2.1. Adult
12.2.2. Geriatric
12.2.3. Pediatric
12.3. Gender
12.3.1. Female
12.3.2. Male
12.4. Income Level
12.4.1. High Income
12.4.2. Low Income
12.4.3. Middle Income
13. Dermatological Therapeutics Market, by End-User
13.1. Introduction
13.2. Home Care Settings
13.3. Hospitals
13.4. Specialty Clinics
14. Americas Dermatological Therapeutics Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Dermatological Therapeutics Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Dermatological Therapeutics Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Aclaris Therapeutics Inc.
17.3.2. Allergan PLC by AbbVie Inc.
17.3.3. Almirall, LLC
17.3.4. Amgen Inc.
17.3.5. AstraZeneca PLC
17.3.6. Bausch Health Companies Inc.
17.3.7. Bristol-Myers Squibb Company
17.3.8. Eli Lilly and Company
17.3.9. Galderma Laboratories, L.P.
17.3.10. GlaxoSmithKline PLC
17.3.11. Johnson & Johnson Services Inc.
17.3.12. Leo Pharma A/S
17.3.13. Merck & Co., Inc.
17.3.14. Novartis AG
17.3.15. Pfizer Inc.
17.3.16. Sun Pharmaceutical Industries, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DERMATOLOGICAL THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. DERMATOLOGICAL THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. DERMATOLOGICAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DERMATOLOGICAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DERMATOLOGICAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DERMATOLOGICAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ANTI-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PUVA THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY UVB THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY HIGH POTENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY LOW POTENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MEDIUM POTENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COMEDONAL ACNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INFLAMMATORY ACNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DIRECT-TO-CONSUMER CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY HIGH INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY LOW INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MIDDLE INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 151. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 154. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 155. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 156. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 157. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 158. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 159. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 160. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 161. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 162. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 165. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 168. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 170. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 171. CANADA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 176. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 177. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 181. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 182. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 183. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 187. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 193. MEXICO DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 263. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 264. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 265. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 266. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 267. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 268. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 269. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 270. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 271. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 272. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 273. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 274. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 277. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 280. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 282. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 283. CHINA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 286. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 288. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 289. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 290. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 291. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 292. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 293. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ACNE, 2018-2030 (USD MILLION)
TABLE 294. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ECZEMA, 2018-2030 (USD MILLION)
TABLE 295. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 296. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY APPLICATION METHOD, 2018-2030 (USD MILLION)
TABLE 299. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY CONSUMER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 304. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY INCOME LEVEL, 2018-2030 (USD MILLION)
TABLE 305. INDIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY BIOLOGIC AGENTS, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPIES, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DERMATOLOGICAL THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DERMATOLOGICA

Companies Mentioned

  • Aclaris Therapeutics Inc.
  • Allergan PLC by AbbVie Inc.
  • Almirall, LLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Galderma Laboratories, L.P.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Leo Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dermatological Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Dermatological Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Dermatological Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Dermatological Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Dermatological Drugs Market Size, Share & Trends Analysis Report By Therapy, By Type, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Dermatological Drugs Market Size, Share & Trends Analysis Report By Therapy, By Type, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Dermatological Drugs Market 2025-2033 - Product Image

Dermatological Drugs Market 2025-2033

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.